Skip to content

Application of Indocyanine Green Fluorescence Imaging Technology in Identifying and Protecting Parathyroid Gland in Differentiated Thyroid Cancer Surgery

Application of Indocyanine Green Fluorescence Imaging Technology in Identifying and Protecting Parathyroid Gland in Differentiated Thyroid Cancer Surgery

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037141
Enrollment
Unknown
Registered
2020-08-27
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid cancer

Interventions

Experimental group 1:Intraoperative injection of ICG 0.1 mL at a concentration of 0.25 mg/mL
Experimental group 2:Intraoperative injection of 0.1ml nano-carbon suspension
Control group:Do not inject any fluid during the operation

Sponsors

Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. The patient's age is >= 18 years old and <= 60 years old; 2. Those who have undergone thyroid surgery for the first time; 3. The preoperative ultrasound examination showed that the thyroid nodule was located on one side, and there was no lateral lymph node or distant metastasis in the neck; 4. Preoperative needle biopsy was diagnosed as DTC, or intraoperative frozen pathology was diagnosed as DTC; 5. Perform lobectomy on the affected side + isthmus resection + lymph node dissection in area VI; 6. The patient was fully informed and signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Posterior sternal thyroid malignant tumor; 2. Patients who have a history of neck radiation; 3. Acute cerebrovascular accident, acute coronary syndrome, arrhythmia state, active gastrointestinal bleeding, etc. 4. Patients with a history of serious chronic diseases or other uncured cancers; 5. Patients with immunosuppressed state; 6. Epilepsy, poisoning, burns, trauma, etc.

Design outcomes

Primary

MeasureTime frame
Parathyroid hormone;

Secondary

MeasureTime frame
Serum calcium concentration;

Countries

China

Contacts

Public ContactMingliang Wang
wml_2902@163.com+86 13801832780

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026